Reports
Sale
Haemoglobinopathies Market Size, Share, Trends, Forecast: By Type: Thalassemia, Sickle Cell Disease, Others; By Therapy: Bone Marrow Transplant, Blood Transfusion, Iron Chelation Therapy, Gene Therapy, Others; Regional Analysis; Market Dynamics: SWOT Analysis, PESTEL Analysis, Porter’s Five Forces Model; Supplier Landscape; 2024-2032
Haemoglobinopathies Market Size
The hemoglobinopathies market was valued at USD 6.9 billion in 2023, driven by the rising incidence of thalassemia and sickle cell anemia across the 8 major markets. The market is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032, with the values likely to rise from USD 7.5 billion in 2024 to USD 15.9 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Haemoglobinopathies Market Outlook
- Recent data reveals that sickle cell anemia affects approximately 100,000 United States citizens, with a higher prevalence in Black or African American individuals. This rising burden of haemoglobinopathies is expected to fuel the market demand for effective therapies.
- Increased focus on the development of novel treatment options, such as gene therapy, which promises potential cures for genetic conditions like sickle cell disease and thalassemia, is one of the major market trends.
- The market value is influenced by the advancements in genetic testing and screening methods, rising healthcare expenditures, and increased research funding aimed at developing new treatments.
Haemoglobinopathies Market Overview
Hemoglobinopathies are a group of inherited blood disorders, affecting hemoglobin in the red blood cells. They are often caused by genetic mutations that lead to alteration of hemoglobin structure, function, or production. Sickle cell anemia and thalassemia are amongst the most common types of hemoglobinopathies. It is estimated that sickle cell anemia affects approximately 100,000 United States citizens, with a higher prevalence in Black or African American individuals (1 in every 365 individuals). Consequently, the haemoglobinopathies market demand is on the rise to combat the rising incidence of diseases.
The haemoglobinopathies market is witnessing advancements in genetic testing and screening methods that are leading to early diagnosis and better management of these disorders. Increased initiatives from the government as well as non-governmental organizations are another factor supporting the market expansion. Moreover, pharmaceutical and biotechnology companies are increasingly focusing on the development and approval of novel treatment options such as gene therapy to treat sickle cell disease and thalassemia.
Haemoglobinopathies Market Growth Drivers
Increased Focus on Early Haemoglobinopathies Diagnosis to Affect the Market Landscape Significantly
The hemoglobinopathies market share is also poised to elevate with rising emphasis on detecting the condition early. In June 2023, Florida Atlantic University released its latest research on developing a portable tool to diagnose and monitor sickle cell anemia. Based on an electrical impedance sensor, the device can analyze the rate of cell sickling as well as the concentration of sickled cells in the body. It can assist in quality treatment and mitigate the comorbidities associated with the disease. The rising innovation in diagnostic capabilities and treatment monitoring is likely to bolster the market growth.
Rising Advancements in Treatment to Meet Rising Haemoglobinopathies Market Demand
The market growth is driven by advancements in treatment and diagnostics. Innovations and growth in gene therapy activities are some of the major market trends. In December 2023, the United States FDA approved Exa-cel, the first CRISPR treatment for sickle cell disease. Lovo-cel, developed by Bluebird Bio, is another gene therapy accepted by the FDA and will be used to treat sickle cell anemia in patients. The increasing integration of novel technologies to aid impactful treatment alternatives is expected to drive market growth in the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Haemoglobinopathies Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Rising Awareness via Screening Programs | To combat the rising incidence of hemoglobinopathies across the globe, many countries have started implementing new screening programs to detect any abnormalities at an early stage. |
| Surge in Strategic Partnerships and Collaborations | Rising partnerships between pharmaceutical companies, healthcare providers, and research institutions are a notable market trend. The collaborations are aimed at developing effective and precise solutions for patients and are anticipated to boost the haemoglobinopathies market share. |
| Preference for Personalized Medicine | Tailoring treatment plans based on the genetic profile of the patient is a significant trend in the market. Precision medicine can help in minimizing side effects while offering improved outcomes for patients. |
| Growth in Investments for Research and Development Activities | To provide new diagnostic methods and treatment, there has been an increase in funding and investments by the government as well as non-governmental organizations. |
Haemoglobinopathies Market Segmentation
Market Breakup by Type
- Thalassemia
- Alpha Thalassemia
- Beta Thalassemia
- Sickle Cell Disease
- Others
Market Breakup by Therapy
- Bone Marrow Transplant
- Blood Transfusion
- Iron Chelation Therapy
- Gene Therapy
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Haemoglobinopathies Market Share
The Gene Therapy Segment is Poised to Hold Substantial Market Value
The market segmentation by therapy includes bone marrow transplant, blood transfusion, iron chelation therapy, and gene therapy, among others. The gene therapy segment is poised to attain a significant market share in the forecast period owing to its potential to cure haemoglobinopathies by directly addressing the genetic root cause. In contrast, traditional treatments like blood transfusions and iron chelation therapy can only manage symptoms which gives gene therapy a major advantage over other conventional therapies. Pharmaceutical companies and venture capitalists are heavily investing in developing gene therapies which is crucial for sustaining research and development activities necessary to bring these therapies from clinical trials to market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Haemoglobinopathies Market Analysis by Region
Based on region, the market report includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is expected to dominate the market share which can be attributed to the presence of major healthcare providers in the region, undergoing significant collaborations and acquisitions to devise the best treatment solutions. The presence of a favorable regulatory environment, such as the U.S. FDA ensuring accelerated approval of innovative treatments including gene therapies for haemoglobinopathies, further stimulates the market growth in the region. With high investments to improve the healthcare and research infrastructure, countries like India are also poised to experience rapid market growth in the forecast period.
Leading Players in the Haemoglobinopathies Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, and strategic initiatives constituting recent funding and investment, partnerships, and collaborations by the leading players. The major companies in the market are as follows:
Bluebird Bio, Inc.
Headquartered in Massachusetts (United States), Bluebird Bio, Inc., is a pioneering biotechnology company that develops gene therapies for patients suffering from severe genetic disorders. It has designed a gene therapy called LYFGENIA™ for sickle cell disease.
Emmaus Medical, Inc.
California-based Emmaus Medical, Inc. is a biopharmaceutical company and has a prominent presence in the treatment domain of sickle cell disease. ENDARI (L-glutamine oral powder) is one of its leading assets to treat sickle cell disease in patients five years of age and older. The company is actively working on expanding the availability of Endari worldwide and is poised to support the haemoglobinopathies market growth.
Prolong Pharmaceuticals, LLC.
Prolong Pharmaceuticals, LLC, headquartered in New Jersey, United States, is known for developing treatments for blood-related disorders and diseases that involve severe anemias, including haemoglobinopathies. The pharmaceutical company is engaged in the clinical development of its investigational drug products aimed at treating sickle cell disease and other conditions.
Other key players in the market include Novartis AG, Pfizer Inc., Sangamo Therapeutics, Inc., CRISPR Therapeutics AG.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Therapy |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Haemoglobinopathies Market Report
- What was the haemoglobinopathies market value in 2023?
- What is the haemoglobinopathies market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on type?
- What are the major therapies in the market?
- What are the major factors aiding the haemoglobinopathies market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of haemoglobinopathies affect the market landscape?
- What are the major haemoglobinopathies market trends?
- Which haemoglobinopathies type will dominate the market share?
- Which test type is expected to have a high market value in the coming years?
- Which technology type will experience the highest demand in the market segment?
- Which therapy is projected to contribute to the highest market growth?
- Who are the key players involved in the haemoglobinopathies market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Haemoglobinopathies Market Overview – 8 Major Markets
3.1 Haemoglobinopathies Market Historical Value (2017-2023)
3.2 Haemoglobinopathies Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Haemoglobinopathies Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Haemoglobinopathies Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality, by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment seeking rate, by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Haemoglobinopathies Market Landscape – 8 Major Markets
8.1 Haemoglobinopathies: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Haemoglobinopathies: Product Landscape
8.2.1 Analysis by Type
8.2.2 Analysis by Therapy
9 Haemoglobinopathies Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Haemoglobinopathies Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Haemoglobinopathies Market Segmentation (2017-2032) - 8 Major Markets
12.1 Haemoglobinopathies Market (2017-2032) by Type
12.1.1 Market Overview
12.1.2 Thalassemia
12.1.2.1 Alpha Thalassemia
12.1.2.2 Beta Thalassemia
12.1.3 Sickle Cell Disease
12.1.4 Others
12.2 Haemoglobinopathies Market (2017-2032) by Therapy
12.2.1 Market Overview
12.2.2 Bone Marrow Transplant
12.2.3 Blood Transfusion
12.2.4 Iron Chelation Therapy
12.2.5 Gene Therapy
12.2.6 Others
12.3 Haemoglobinopathies Market (2017-2032) by Region
12.3.1 Market Overview
12.3.2 United States
12.3.3 EU-4 and the United Kingdom
12.3.3.1 Germany
12.3.3.2 France
12.3.3.3 Italy
12.3.3.4 Spain
12.3.3.5 United Kingdom
12.3.4 Japan
12.3.5 India
13 United States Haemoglobinopathies Market (2017-2032)
13.1 United States Haemoglobinopathies Market Historical Value (2017-2023)
13.2 United States Haemoglobinopathies Market Forecast Value (2024-2032)
13.3 United States Haemoglobinopathies Market (2017-2032) by Type
13.3.1 Market Overview
13.3.2 Thalassemia
13.3.2.1 Alpha Thalassemia
13.3.2.2 Beta Thalassemia
13.3.3 Sickle Cell Disease
13.3.4 Others
13.4 United States Haemoglobinopathies Market (2017-2032) by Therapy
13.4.1 Market Overview
13.4.2 Bone Marrow Transplant
13.4.3 Blood Transfusion
13.4.4 Iron Chelation Therapy
13.4.5 Gene Therapy
13.4.6 Others
14 EU-4 and United Kingdom Haemoglobinopathies Market (2017-2032)
14.1 EU-4 and United Kingdom Haemoglobinopathies Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Haemoglobinopathies Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Haemoglobinopathies Market (2017-2032) by Type
14.3.1 Market Overview
14.3.2 Thalassemia
14.3.2.1 Alpha Thalassemia
14.3.2.2 Beta Thalassemia
14.3.3 Sickle Cell Disease
14.3.4 Others
14.4 EU-4 and United Kingdom Haemoglobinopathies Market (2017-2032) by Therapy
14.4.1 Market Overview
14.4.2 Bone Marrow Transplant
14.4.3 Blood Transfusion
14.4.4 Iron Chelation Therapy
14.4.5 Gene Therapy
14.4.6 Others
15 Japan Haemoglobinopathies Market
15.1 Japan Haemoglobinopathies Market Historical Value (2017-2023)
15.2 Japan Haemoglobinopathies Market Forecast Value (2024-2032)
15.3 Japan Haemoglobinopathies Market (2017-2032) by Type
15.3.1 Market Overview
15.3.2 Thalassemia
15.3.2.1 Alpha Thalassemia
15.3.2.2 Beta Thalassemia
15.3.3 Sickle Cell Disease
15.3.4 Others
15.4 Japan Haemoglobinopathies Market (2017-2032) by Therapy
15.4.1 Market Overview
15.4.2 Bone Marrow Transplant
15.4.3 Blood Transfusion
15.4.4 Iron Chelation Therapy
15.4.5 Gene Therapy
15.4.6 Others
16 India Haemoglobinopathies Market
16.1 India Haemoglobinopathies Market (2017-2032) Historical Value (2017-2023)
16.2 India Haemoglobinopathies Market (2017-2032) Forecast Value (2024-2032)
16.3 India Haemoglobinopathies Market (2017-2032) by Type
16.3.1 Market Overview
16.3.2 Thalassemia
16.3.2.1 Alpha Thalassemia
16.3.2.2 Beta Thalassemia
16.3.3 Sickle Cell Disease
16.3.4 Others
16.4 India Haemoglobinopathies Market (2017-2032) by Therapy
16.4.1 Market Overview
16.4.2 Bone Marrow Transplant
16.4.3 Blood Transfusion
16.4.4 Iron Chelation Therapy
16.4.5 Gene Therapy
16.4.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 Japan PMDA
17.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by Year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Strategic Initiatives
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Market Share by Top 5 Companies
22.2 Bluebird Bio, Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Emmaus Medical, Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Prolong Pharmaceuticals, LLC.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Novartis AG
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Pfizer, Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Sangamo Therapeutics, Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 CRISPR Therapeutics AG
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
23 Haemoglobinopathies Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER